Trillium Therapeutics (TSE:TRIL) Shares Up 0.5%

Shares of Trillium Therapeutics Inc. (TSE:TRIL) shot up 0.5% during trading on Monday . The company traded as high as C$23.45 and last traded at C$23.33. 60,423 shares were traded during mid-day trading, a decline of 64% from the average session volume of 166,586 shares. The stock had previously closed at C$23.22.

Trillium Therapeutics Price Performance

The company has a market cap of C$2.45 billion and a price-to-earnings ratio of -34.06. The company has a debt-to-equity ratio of 0.27, a current ratio of 12.04 and a quick ratio of 11.54. The stock’s 50-day moving average is C$23.33.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides.